Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care

Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care

Epioxa Provides the Ophthalmic Community and Patients with the First and Only FDA-Approved, Incision-Free, Topical Drug Therapy for Keratoconus, a Sight-Threatening Rare DiseaseALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today the commercial availabili…

Glaukos Launches Epioxa Epithelium-On Therapy for Keratoconus

Key Takeaways Glaukos has launched Epioxa, the first FDA-approved epithelium-on corneal cross-linking therapy The therapy is designed to improve patient comfort, reduce pain, and shorten recovery time while delivering clinically meaningful outcomes The company is expanding patient access and awareness efforts, including financial assistance programs and early detection initiatives Glaukos announced the commercial availability of Epioxa H…